These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28461223)

  • 1. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia.
    Talpos JC
    Drug Discov Today; 2017 Jul; 22(7):1017-1026. PubMed ID: 28461223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.
    Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM
    Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Drugs for Cognition in Schizophrenia.
    Yang YS; Marder SR; Green MF
    Clin Pharmacol Ther; 2017 Feb; 101(2):191-193. PubMed ID: 27706797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD; Keefe RS
    Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
    Carter CS; Barch DM
    Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the cholinesterase inhibitors in the treatment of schizophrenia.
    Pae CU
    Expert Opin Investig Drugs; 2013 Mar; 22(3):293-8. PubMed ID: 23330829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond.
    Meyer U; Schwarz MJ; Müller N
    Pharmacol Ther; 2011 Oct; 132(1):96-110. PubMed ID: 21704074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of Oxytocin in the Treatment of Schizophrenia.
    Shilling PD; Feifel D
    CNS Drugs; 2016 Mar; 30(3):193-208. PubMed ID: 26895254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive impairment in schizophrenia.
    Keefe RS; Harvey PD
    Handb Exp Pharmacol; 2012; (213):11-37. PubMed ID: 23027411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.
    Remington G; Agid O; Foussias G
    Expert Rev Neurother; 2011 Apr; 11(4):589-607. PubMed ID: 21469931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug initiatives to improve cognitive function.
    Marder SR
    J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.